CIK 0001540159 · Non-accelerated filer<br>Smaller reporting company
Edesa Biotech, Inc.
Sign in to watch- Ticker
- EDSA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Sep 30
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- (905) 475-1234
- Business address
- C/O FASKEN MARTINEAU DUMOULIN LLP, 333 BAY STREET, SUITE 2400, TORONTO, Ontario, Canada, M5H 2T6
- Former names
- Stellar Biotechnologies, Inc.
- S-3 Offering Registration Statement
- 4 Open-market buy Chief Executive Officer bought 20,000 shares at $1.60 ($32,078)
- 4 Open-market buy President bought 3,000 shares at $1.49 ($4,483)
- 4 Open-market buy President bought 3,000 shares at $1.61 ($4,817)
- 4 Open-market buy Chief Executive Officer bought 5,000 shares at $1.92 ($9,599)
- 4 Open-market buy President bought 3,500 shares at $1.74 ($6,090)
- 4 Open-market buy Chief Executive Officer bought 2,000 shares at $1.80 ($3,600)
- 8-K Event Shareholder vote results
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- EFFECT Other Notice of Effectiveness
- 424B4 Offering Prospectus
- UPLOAD Other SEC-generated Letter
- CORRESP Other Correspondence Between Filers and SEC Staff
- S-1 Offering Registration Statement
- D Other Notice of Sales of Unregistered Securities
- DEF 14A Proxy Proxy Statement
- 4 Open-market buy Chief Executive Officer bought 2,000 shares at $2.99 ($5,972)
- 4 Open-market buy Chief Executive Officer bought 2,000 shares at $3.05 ($6,098)
- 4 Derivatives Options or other derivatives
Page 13 of 38 · 753 filings